Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6188491 | Journal of Reproductive Immunology | 2016 | 6 Pages |
Abstract
Galectin-1 (gal-1), a member of a family of conserved β-galactoside-binding proteins, has been shown to exert a key role during gestation. Though gal-1 is expressed at higher levels in the placenta from HELLP patients, it is still poorly understood whether systemic gal-1 levels also differ in HELLP patients. In the present study, we evaluated the systemic expression of gal-1, together with the angiogenic factors, placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) in conjunction with HELLP syndrome severity. Systemic levels of gal-1 and sFlt-1 were elevated in patients with both early- and late-onset HELLP syndrome as compared to healthy controls. In contrast, peripheral PlGF levels were decreased in early- and late-onset HELLP. A positive correlation between systemic gal-1 levels and sFlt-1/PlGF ratios was found in early onset HELLP patients. Our results show that HELLP syndrome is associated with increased circulating levels of gal-1; integrating systemic gal-1 measurements into the diagnostic analyses of pregnant women may provide more effective prediction of HELLP syndrome development.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Annegret Schnabel, Sandra M. Blois, Peter Meint, Nancy Freitag, Wolfgang Ernst, Gabriela Barrientos, Melanie L. Conrad, Matthias Rose, Birgit Seelbach-Göbel,